#USA #Phoenix #Wound Care #BioLab Holdings #CAMP Platform

BioLab Holdings Reports Progress on Clinical Trials

BioLab Holdings, Inc., a medical technology firm based in Phoenix, is making substantial strides in its clinical trials aimed at advancing wound care solutions. The company is committed to enhancing tissue restoration through innovation and strategic partnerships. In their recent announcements, BioLab shared updates on multiple trials evaluating their Cellular, Acellular, and Matrix-like Products (CAMPs), along with other emerging technologies.

Dr. Marshall Medley, the Chief Medical Officer at BioLab, emphasized the importance of clinical research for the company's mission: "Advancing clinical research is central to our mission of delivering safe, high-quality solutions that improve outcomes for patients with chronic wounds.” With this focus, BioLab aims to build a robust clinical evidence base while expanding treatment options for healthcare providers and patients.

Progress on Clinical Trials

BioLab's clinical foundation has been strengthened through extensive retrospective research. A study previously published highlighted the efficacy of their product, Membrane Wrap™, in treating Diabetic Foot Ulcers (DFUs), demonstrating superior results compared to traditional standard of care. This data was featured in Wound Care Today, signifying the organization's commitment to providing evidence-driven solutions in wound care.

Another ongoing study titled "Accelerating Recovery from Global Burden to Local Action Placental-Based Solutions for Complex Pressure Ulcers Using Real-World Evidence" is in the publication phase and is expected to appear in Wounds International soon. It focuses on the same Membrane Wrap™ for pressure ulcers, highlighting BioLab's expansive research endeavors across various types of chronic wounds.

BioLab has successfully completed enrollment in its CAMP RWE trial, which employs a recent multicenter hybrid approach to compare the outcomes of prospective cohorts treated with tri-layer and single-layer amnion grafts against matched retrospective controls. This trial will yield data on the effectiveness of Membrane Wrap Lite™ and Tri-Membrane Wrap™ in the DFU and Venous Leg Ulcer (VLU) populations, with an expected completion date set for August 2026.

Additionally, the company's BIOCAMP trial—another multicenter, prospective, randomized controlled trial—is actively enrolling patients to investigate the efficacy of human placental membrane products combined with standard of care versus standard of care alone for treating non-healing DFUs and VLUs. The study is notable for allowing the simultaneous evaluation of various products and wound types, with 266 patients currently in screening or enrollment and 169 already randomized.

Upcoming Trials and Innovations

As BioLab looks forward, several new studies are on the horizon to further refine its research pipeline. The CAMPR-II trial, mirroring the CAMP RWE design, will investigate novel products, Membrane Wrap Hydro™ and Imbed’s Microlyte™, targeting DFUs and VLUs. This study has received Institutional Review Board approval and is set to commence patient enrollment soon.

In conjunction with this, BioLab is initiating the BIO-SEE trial, recognized as the first U.S.-led prospective study focusing on bacterial detection capabilities through its cureVision documentation device which utilizes fluorescent imaging technology for assessing tissue. This study aims to compare results from the new technology against existing methods and tissue biopsy data, with site visits currently underway.

Chronic wounds, including DFUs, VLUs, and pressure ulcers, present considerable challenges for the healthcare system, leading to increased complications and costs. However, through its extensive array of clinical trials, BioLab Holdings is committed to shifting the narrative towards evidence-based solutions that enhance healing outcomes and elevate patient care quality.

For further details on BioLab Holdings, Inc. and its clinical research activities, visit biolabholdings.com.

About BioLab Holdings, Inc.

BioLab Holdings, Inc. specializes in medical technology focused on tissue restoration through innovation, strategic alliances, and commercialization. The company strategically merges clinician-driven product strategies with entrepreneurial partnerships to develop and deliver high-impact technologies that aim for improved patient outcomes across different healthcare settings.